GSK Follows Oncology Rivals’ Playbook in Search of Growth

GSK Plc is planning five simultaneous late-stage trials for a cancer drug it hopes will be a blockbuster, as new Chief Executive Officer Luke Miels tries to revitalize a company not known for its risk-taking.